Operating mechanism of dry eye treatment with E-Eye
Quantified and cumulative efficiencyAll the studies conducted showed improvement in the quality of meibum but also on the compression of the meibomian glands. This improvement will last: About a week after the initial treatment. Two to three weeks after the second. Between 6 months to 3 years after the third session. The effect is cumulative.
Figure: Total symptom scores.
Notes: The total score of the 10 single symptoms were defined as the total symptom scores. (Dryness, Foreign body sensation, Itching, Burning, Visual Fatigue, Blurred Vision, Sensitivity to light, Watering, Secretion disturbance, Pain). *Compared to the baseline, the total symptom score significantly decreased at the time of D15, D45 and D75 (P<0.01). **Between the visits of D15 and D45, the total score continuously decreased (P<0.01), while between the visits of D45 and D75, no significant difference was observed (P=0.85).
An instant improvementThe stimulation leads to the Meibomian glands returning to their normal function in a very short time (a couple of hours) following the treatment.
In the long runThe treatment effects last 6 months to 3 years after the 3rd to 4th sessions. In 60% of cases, effects persist beyond 3 years after the treatment. According to the Oxford scheme (0,I, II, III, IV), patients with lower grade (1 and 2) are "easy” candidates that go down from 1 to 2 grades after the first 3 sessions.
Figure: Oxford grading system
Scientifically proven efficiency by 4 clinical studies
1 - Clinical trial in France, 2012
Study:Dr Christian Malbrel, Ophthalmologist in Reims, France, undertook a clinical study in 2012 on 150 patients with MGD.
Results:Results show 90% satisfaction rate after a serie of 3 treatments on day 1, 15 and 45. Read more
2 - Clinical trial in New Zealand, 2014
Study:Associate Professor Jennifer P. Craig from the Ocular Surface Laboratory within The University of Auckland’s Department of Ophthalmology, has published results of a prospective, double-masked clinical study using E-Eye technology for the treatment of MGD. This study has been published in the Association for Research and Vision in Ophthalmology’s (ARVO’s) journal of Investigative Ophthalmology & Visual Science.
Results:Here are the results 45 days after 3 treatments:
- Significant improvement in the Non-Invasive Tear Break Up Time (NIBUT) in the treated eye but not in the control one.
- Significant improvement of the tear Lipid Layer Grade (LLG) measured with a TearScope.
- 86% of participants noted reduced symptoms in the treated eye (SPEED score).